Accelerating the manufacturing of HIV Env protein vaccines for early phase clinical evaluation
This commentary discusses the benefits in terms of time savings and reduced costs of goods in using transient electroporation and immuno-affinity purification as an alternative to the traditional manufacturing approaches for the CGMP manufacturing of HIV Envelope protein immunogens for use in invest...
Saved in:
| Main Author: | Michael N. Pensiero |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-08-01
|
| Series: | npj Vaccines |
| Online Access: | https://doi.org/10.1038/s41541-025-01169-y |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Safety and Immunogenicity of a rAd35-EnvA Prototype HIV-1 Vaccine in Combination with rAd5-EnvA in Healthy Adults (VRC 012).
by: Michelle C Crank, et al.
Published: (2016-01-01) -
Env-pseudoviruses based on the HIV-1 genetic variant circulating in Siberia
by: N. B. Rudometova, et al.
Published: (2025-07-01) -
Accelerated cGMP production of near-native HIV-1 Env trimers following electroporation transfection and immunogenicity analysis
by: Shridhar Bale, et al.
Published: (2025-08-01) -
Convergence and divergence of B cell responses in two HIV-1 Env immunizations in Rhesus macaques
by: Jenna M. DeLuca, et al.
Published: (2025-05-01) -
The Overexpression of an <i>EnvZ</i>-like Protein Improves the Symbiotic Performance of Mesorhizobia
by: José Rodrigo da-Silva, et al.
Published: (2025-05-01)